Manguso, Robert T.

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

Miller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., et al. (2019) · Nature Immunology

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 2,087

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 1,147

Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade

Ishizuka, J. J., Manguso, R. T., Cheruiyot, C. K., Bi, K., Panda, A., Iracheta-Vellve, A., Miller, B. C., Du, P. P., Yates, K. B., Dubrot, J., et al. (2019) · Nature

Cancer Immunotherapy and BiomarkersRNA regulation and disease

Cited by 697

Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity

Griffin, G. K., Wu, J., Iracheta-Vellve, A., Patti, J. C., Hsu, J., Davis, T., Dele-Oni, D., Du, P. P., Halawi, A. G., Ishizuka, J. J., et al. (2021) · Nature

Cancer Immunotherapy and BiomarkersEpigenetics and DNA Methylation

Cited by 370

In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer

Dubrot, J., Du, P. P., Lane-Reticker, S. K., Kessler, E. A., Muscato, A. J., Mehta, A., Freeman, S. S., Allen, P. M., Olander, K. E., Ockerman, K. M., et al. (2022) · Nature Immunology

Cancer Immunotherapy and BiomarkersImmune Cell Function and Interaction

Cited by 218

An expanded universe of cancer targets

Hahn, W. C., Bader, J. S., Braun, T. P., Califano, A., Clemons, P. A., Druker, B. J., Ewald, A. J., Fu, H., Jagu, S., Kemp, C. J., et al. (2021) · Cell

Cancer Genomics and DiagnosticsChromatin Remodeling and Cancer

Cited by 213

Targeting TBK1 to overcome resistance to cancer immunotherapy

Sun, Y., Revach, O.-Y., Anderson, S., Kessler, E. A., Wolfe, C. H., Jenney, A., Mills, C. E., Robitschek, E. J., Davis, T. G. R., Kim, S., et al. (2023) · Nature

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 174

DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming

Gritti, I., Wan, J., Weeresekara, V., Vaz, J. M., Tarantino, G., Bryde, T. H., Vijay, V., Kammula, A. V., Kattel, P., Zhu, S., et al. (2025) · Cancer Discovery

Hepatocellular Carcinoma Treatment and PrognosisChromatin Remodeling and Cancer

Cited by 20